News

Apply now for the ATCC Innovation Challenge

ATCC is excited to launch their 2025 Innovation Challenge, inviting researchers to explore bold, creative applications of their ThawReady™ Assay Ready Cells, an innovative line of products  designed to accelerate cell-based assays and eliminate the need for lengthy cell expansion and banking prior to starting bioassays, saving valuable time and money.

Running through November 30, 2025, the challenge offers researchers an opportunity to win free ThawReady™ products and gain visibility through collaboration with ATCC in webinars, conference showcases, and other scientific platforms. To enter, researchers must submit a short proposal (up to 1000 characters) describing how they plan to use ThawReady™ cells in their innovative research. Winning entries will receive complimentary products and the opportunity to share their work with the broader scientific community.

Two models are available for the challenge:

ThawReady™ THP-1 (TIB-202-AR)

  • Derived from a human monocytic leukemia patient.
  • Ideal for immunology, toxicology, and cancer research.
  • Supports assays such as monocyte differentiation, phagocytosis, and co-culture studies.
  • Preserved in a chemically defined, animal-free formulation.
  • Ready to use upon thawing with ≥80% viability.

 ThawReady™ THP-1 NF-κB-Luc2 (TIB-202-NFkB-LUC2-AR)

  • Engineered to express luciferase under NF-κB control.
  • Enables sensitive, quantitative analysis of NF-κB activation.
  • Demonstrates over 200-fold increase in luminescence upon LPS stimulation.
  • Maintains functionality and morphology post-thaw, even after extended rest periods.
  • Suitable for drug screening, pathway analysis, and biocompatibility testing.

 

Recent News

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical

11/07/2025

Dan Myers Named Director of Virginia SBDC, Innovation Commercialization Assistance Program to Accelerate Tech-Driven Growth in the Commonwealth

The Virginia Small Business Development Center (SBDC) is pleased to announce that Dan Myers has been named the new Director for the Virginia SBDC – Innovation Commercialization Assistance Program (ICAP). Dan, a seasoned innovation strategist, will lead the Virginia SBDC – ICAP program that is designed to help Virginia small businesses turn ideas into commercial

11/06/2025

Luna Labs’ MedSim Product Lines Acquired by Integrated Medcraft

Integrated MedCraft LLC today announced it has acquired the TrueClot and Dislotech product lines from Luna Labs. This announcement is more than a successful transaction. It is an example of innovation being accelerated with the right strategic partner. We built Luna Labs with a clear mission to incubate, accelerate, and grow technologies to the point